Z Lakkis1, G Manceau2, V Bridoux3, A Brouquet4, S Kirzin5, L Maggiori6, C de Chaisemartin7, J H Lefevre8, Y Panis6. 1. Department of Digestive and Oncologic Surgery, University Hospital of Besancon, Franche-Comté University Besancon, Besancon, France. 2. Department of Digestive and Hepato-Pancreato-Biliary Surgery, Pitié-Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France. 3. Department of Digestive Surgery, Rouen University Hospital, Rouen, France. 4. Department of Digestive and Oncologic Surgery, Bicêtre Hospital, Assistance Publique-Hôpitaux de Paris, University Institute of Cancerology (Paris VI), Pierre and Marie Curie University, Paris, France. 5. Department of Colorectal and Oncological Surgery, Purpan Hospital and Toulouse III University, Toulouse, France. 6. Department of Colorectal Surgery, Beaujon Hospital, Assistance Publique-Hôpitaux de Paris, University Paris VII, Clichy, France. 7. Department of Surgical Oncology, Institut Paoli-Calmettes, Marseille, France. 8. Department of Digestive Surgery, Saint-Antoine Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
Abstract
AIM: Rectal cancer is a malignant disease requiring multidisciplinary management. In view of the increasing number of studies published over the past decade, a comprehensive update is required to draw recommendations for clinical practice mandated by the French Research Group of Rectal Cancer Surgery and the French National Coloproctology Society. METHOD: Seven questions summarizing the treatment of rectal cancer were selected. A search for evidence in the literature from January 2004 to December 2015 was performed. A drafting committee and a large group of expert reviewers contributed to validate the statements. RESULTS: Recommendations include the indications for neoadjuvant therapy, the quality criteria for surgical resection, the management of postoperative disordered function, the role of local excision in early rectal cancer, the place of conservative strategies after neoadjuvant treatment, the management of synchronous liver metastases and the indications for adjuvant therapy. A level of evidence was assigned to each statement. CONCLUSION: The current clinical practice guidelines are useful for the treatment of rectal cancer. Some statements require a higher level of evidence due to a lack of studies. Colorectal Disease
AIM: Rectal cancer is a malignant disease requiring multidisciplinary management. In view of the increasing number of studies published over the past decade, a comprehensive update is required to draw recommendations for clinical practice mandated by the French Research Group of Rectal Cancer Surgery and the French National Coloproctology Society. METHOD: Seven questions summarizing the treatment of rectal cancer were selected. A search for evidence in the literature from January 2004 to December 2015 was performed. A drafting committee and a large group of expert reviewers contributed to validate the statements. RESULTS: Recommendations include the indications for neoadjuvant therapy, the quality criteria for surgical resection, the management of postoperative disordered function, the role of local excision in early rectal cancer, the place of conservative strategies after neoadjuvant treatment, the management of synchronous liver metastases and the indications for adjuvant therapy. A level of evidence was assigned to each statement. CONCLUSION: The current clinical practice guidelines are useful for the treatment of rectal cancer. Some statements require a higher level of evidence due to a lack of studies. Colorectal Disease